<![CDATA[Autogene Cevumeran Trial Terminated in Resected Colorectal Cancer]]>
Phase 2negativeautogene cevumeranNegative
AI Analysis
Summary
BioNTech terminated a Phase 2 trial of autogene cevumeran in ctDNA-positive, resected colorectal cancer after the Data Safety Monitoring Board identified an overall survival imbalance. This is a significant setback for the candidate in this indication.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Trial terminated by DSMB due to overall survival imbalance
Importance:8/10
Sentiment:
-0.90
Phase 2 terminationcolorectal cancersafety concernoverall survival imbalance
Related Companies
Read the original article
Published by Cancer Network on August 31, 2026 2:57 PM